Clinical Trial: Safety and Pharmacokinetic Study of Anthrax Immune Globulin Derived From Human Serum

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Safety and Pharmacokinetics of Anthrax Immune Globulin Intravenous (Human), NP-015, in Healthy Volunteers.

Brief Summary: The purpose of the study is to assess the pharmacokinetics of three doses of NP-015 (210, 420 or 840 units TNA) in healthy volunteers. To evaluate the safety of NP-015 based on adverse events and laboratory assessments. To determine the dose proportionality relation of three different doses of NP-015.